Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aralia root bark extract
- Development stage
- Unknown
- Administration
- Oral
01
Overview
Aralia root bark extract (ARBE) is a botanical extract derived from the root bark of plants in the Aralia genus, notably *Aralia elata* and *Aralia taibaiensis*. Its primary bioactive components are triterpenoid saponins, including araloside A, B, and C. ARBE has been studied for its antidiabetic, antioxidant, antiglycation, and antiulcer properties. In clinical research, it has been evaluated as a combination therapy with glipizide for type 2 diabetes mellitus, where it showed potential in reducing HbA1c and LDL-C levels. It is not a proprietary drug developed by a single company but is a subject of academic and traditional medicine research.
- Other names
- ARBEAralia elata root bark extractAralia taibaiensis root bark extract
Beyond the preview
Go deeper on aralia root bark extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aralia root bark extract.